| Names | |
|---|---|
|
IUPAC name
4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide
|
|
| Other names
LY-334,370
|
|
| Identifiers | |
|
3D model (Jmol)
|
|
| ChemSpider | |
| MeSH | C108218 |
|
PubChem CID
|
|
|
|
|
|
| Properties | |
| C21H22FN3O | |
| Molar mass | 351.42 g/mol |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
|
|
|
| Infobox references | |
LY-334370 is a selective 5-HT1F receptor agonist which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals.